Market Place
Sourcing Support
Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Adagene Announces Poster Presentations On ADG126 At SITC
09 Oct 2024 //
GLOBENEWSWIRE
Adagene Presents ADG126 Combo Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Adagene to Participate in Investor Conferences in September
29 Aug 2024 //
GLOBENEWSWIRE
Adagene Reports H1 2024 Results And Provides Corporate Update
25 Jul 2024 //
GLOBENEWSWIRE
Adagene To Present ADG126-Pembrolizumab Combo Data At ESMO Congress
12 Jul 2024 //
GLOBENEWSWIRE
Adagene to Present at Investor Conferences in June
22 May 2024 //
GLOBENEWSWIRE
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
29 Mar 2024 //
GLOBENEWSWIRE
Adagene Appoints Heinz-Josef Lenz FACP to Strategic Advisory Board
07 Mar 2024 //
GLOBENEWSWIRE
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
27 Feb 2024 //
GLOBENEWSWIRE
Adagene Announces Progress and Expansion of Collaboration Program for Masked
09 Feb 2024 //
GLOBENEWSWIRE
Adagene Presents Results Reinforcing Best-in-Class Profile of ADG126
16 Jan 2024 //
GLOBENEWSWIRE
Adagene To Present Results of anti-CTLA-4 SAFEbody ADG126 with Pembrolizumab
04 Jan 2024 //
GLOBENEWSWIRE
Adagene Presents Data Demonstrating Best-in-Class Therapeutic Index for ADG126
03 Nov 2023 //
GLOBENEWSWIRE
Adagene Announces Presentation on Optimal Dose Selection for ADG126
12 Oct 2023 //
GLOBENEWSWIRE
Adagene to Present at Investor and Scientific Conferences in September
07 Sep 2023 //
GLOBENEWSWIRE
ADC Therapeutics calls it quits on Adagene solid tumor collab
31 Aug 2023 //
FIERCE BIOTECH
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis
04 May 2023 //
GLOBENEWSWIRE
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing
18 Apr 2023 //
GLOBENEWSWIRE
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
28 Mar 2023 //
GLOBENEWSWIRE
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody, ADG126
14 Mar 2023 //
GLOBENEWSWIRE
Adagene Appoints Professor Aurlien Marabelle to Advisory Board
05 Mar 2023 //
GLOBENEWSWIRE
Adagene Announces Data Demonstrating Safety of Anti-CTLA-4 SAFEbody ADG126
09 Jan 2023 //
GLOBENEWSWIRE
Adagene to Collaborate to Evaluate Anti-CTLA-4 SAFEbody ADG126 with Roche
16 Dec 2022 //
GLOBENEWSWIRE
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
21 Nov 2022 //
GLOBENEWSWIRE
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116
10 Nov 2022 //
GLOBENEWSWIRE
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116
11 Oct 2022 //
GLOBENEWSWIRE
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety
10 Sep 2022 //
GLOBENEWSWIRE
Adagene Reports Financial Results for the Six Months Ended June 30, 2022
30 Aug 2022 //
GLOBENEWSWIRE
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
29 Jun 2022 //
GLOBENEWSWIRE
Adagene Announces Publication at ASCO of Dose Escalation Data of ADG126
26 May 2022 //
GLOBENEWSWIRE
Adagene to Participate in Investor Conferences in May and June
12 May 2022 //
GLOBENEWSWIRE
Adagene Presents Data on First and Best-in-Class Potential for Abs at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
31 Mar 2022 //
GLOBENEWSWIRE
FDA Clears Adagene`s P 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody
16 Mar 2022 //
GLOBENEWSWIRE
Adagene says 4 Posters on Robust PC Pipeline of Ab-Based Tx
08 Mar 2022 //
GLOBENEWSWIRE
Sanofi looks for a `safe` bet in $2.5B tie up for Adagene tech
03 Mar 2022 //
FIERCEBIOTECH
Adagene Announces First Patient Dosed with ADG106 and ADG116
27 Jan 2022 //
GLOBENEWSWIRE
Adagene Begins Dosing in Phase 1b/2 Clinical Trial of ADG106 + Nivolumab
13 Jan 2022 //
GLOBENEWSWIRE
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody
22 Dec 2021 //
GLOBENEWSWIRE
Adagene Announces Poster Presentations of Clinical Data for at ESMO
22 Nov 2021 //
GLOBENEWSWIRE
Adagene Unveils Preclinical Data from Two Transformative Antibody Programs
04 Nov 2021 //
GLOBENEWSWIRE
Adagene Establishes Collaboration for Trial of ADG106 in Combino with Nivolumab
27 Oct 2021 //
GLOBENEWSWIRE
Adagene Reports Financial Results for 6 Months Ended June 30, 2021
26 Aug 2021 //
GLOBENEWSWIRE
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
07 Jul 2021 //
GLOBENEWSWIRE
Adagene Announces Inclusion in FTSE Russell Indexes
16 Jun 2021 //
GLOBENEWSWIRE
Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137
18 May 2021 //
GLOBENEWSWIRE
Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126
13 Apr 2021 //
GLOBENEWSWIRE
Adagene Announces Clinical Advancement for ADG116
29 Mar 2021 //
BIOSPACE
Adagene Announces First Patients Dosed in Global Phase 1 Trial of ADG126
15 Mar 2021 //
GLOBENEWSWIRE
A pair of biotechs prepares to hit Nasdaq, as total 2021 IPO raise quickly $3B
12 Feb 2021 //
ENDPTS
Chinese cancer biotech Adagene sets terms for $132 million US IPO
03 Feb 2021 //
NASDAQ
Exelixis and Adagene Enter into Collaboration and License Agreement
01 Feb 2021 //
BUSINESSWIRE
Adagene plans $125M IPO to challenge BMS and Pfizer
20 Jan 2021 //
FIERCEBIOTECH
Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer
20 Jan 2021 //
FIERCEBIOTECH
Adagene Achieves CAR-T Collaboration Milestone
12 Jan 2021 //
CONTRACTPHARMA
Adagene Announces Strategic Collaboration Agreement with Tanabe Research Lab
09 Jun 2020 //
PRNEWSWIRE
Adagene Completes $69 Million Series D Financing
13 Jan 2020 //
BIOSPECTRUMASIA
ADC Therapeutics and Adagene Announce License Agreement
24 Apr 2019 //
GLOBENEWSWIRE
Adagene to evaluate dynamic precision library platform with Celgene
04 Mar 2019 //
BIOSPECTRUMASIA
